352 related articles for article (PubMed ID: 27149858)
1. Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Leuci V; Maione F; Rotolo R; Giraudo E; Sassi F; Migliardi G; Todorovic M; Gammaitoni L; Mesiano G; Giraudo L; Luraghi P; Leone F; Bussolino F; Grignani G; Aglietta M; Trusolino L; Bertotti A; Sangiolo D
J Transl Med; 2016 May; 14(1):119. PubMed ID: 27149858
[TBL] [Abstract][Full Text] [Related]
2. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin.
Shen Y; Li S; Wang X; Wang M; Tian Q; Yang J; Wang J; Wang B; Liu P; Yang J
J Exp Clin Cancer Res; 2019 Oct; 38(1):427. PubMed ID: 31656203
[TBL] [Abstract][Full Text] [Related]
3. Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy.
Cheng L; Liu W; Zhong C; Ni P; Ni S; Wang Q; Zhang Q; Zhang J; Liu J; Xu M; Yao X; Cen X; Wang G; Jiang C; Zhou F
J Ethnopharmacol; 2021 Apr; 270():113770. PubMed ID: 33388426
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
Tóvári J; Gilly R; Rásó E; Paku S; Bereczky B; Varga N; Vágó A; Tímár J
Cancer Res; 2005 Aug; 65(16):7186-93. PubMed ID: 16103069
[TBL] [Abstract][Full Text] [Related]
5. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
Kim SJ; Jung KH; Son MK; Park JH; Yan HH; Fang Z; Kang YW; Han B; Lim JH; Hong SS
Cancer Lett; 2017 Sep; 403():339-353. PubMed ID: 28688971
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
7. Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.
Patras L; Sylvester B; Luput L; Sesarman A; Licarete E; Porfire A; Muntean D; Drotar DM; Rusu AD; Nagy AL; Catoi C; Tomuta I; Vlase L; Banciu M; Achim M
Cancer Biol Ther; 2017 Aug; 18(8):616-626. PubMed ID: 28696813
[TBL] [Abstract][Full Text] [Related]
8. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
9. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Lu L; Payvandi F; Wu L; Zhang LH; Hariri RJ; Man HW; Chen RS; Muller GW; Hughes CC; Stirling DI; Schafer PH; Bartlett JB
Microvasc Res; 2009 Mar; 77(2):78-86. PubMed ID: 18805433
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
11. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).
Liu WM; Henry JY; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Br J Cancer; 2009 Sep; 101(5):803-12. PubMed ID: 19638977
[TBL] [Abstract][Full Text] [Related]
13. COMP-Ang1 potentiates the antitumor activity of 5-fluorouracil by improving tissue perfusion in murine Lewis lung carcinoma.
Hwang JA; Lee EH; Kim HW; Park JB; Jeon BH; Cho CH
Mol Cancer Res; 2009 Dec; 7(12):1920-7. PubMed ID: 19952114
[TBL] [Abstract][Full Text] [Related]
14. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Yao M; Zhou W; Sangha S; Albert A; Chang AJ; Liu TC; Wolfe MM
Clin Cancer Res; 2005 Feb; 11(4):1618-28. PubMed ID: 15746067
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Mangiameli DP; Blansfield JA; Kachala S; Lorang D; Schafer PH; Muller GW; Stirling DI; Libutti SK
J Transl Med; 2007 Jul; 5():38. PubMed ID: 17640369
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Ng SS; MacPherson GR; Gütschow M; Eger K; Figg WD
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4192-7. PubMed ID: 15217957
[TBL] [Abstract][Full Text] [Related]
17. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
18. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab.
Weisshardt P; Trarbach T; Dürig J; Paul A; Reis H; Tilki D; Miroschnik I; Ergün S; Klein D
Histochem Cell Biol; 2012 Mar; 137(3):391-401. PubMed ID: 22193946
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.
Tang YC; Zhang Y; Zhou J; Zhi Q; Wu MY; Gong FR; Shen M; Liu L; Tao M; Shen B; Gu DM; Yu J; Xu MD; Gao Y; Li W
Int J Oncol; 2018 Jan; 52(1):127-138. PubMed ID: 29115601
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
